Your browser doesn't support javascript.
loading
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin, Fabrice; Pujals, Anais; Pelletier, Laura; Bohers, Elodie; Camus, Vincent; Mareschal, Sylvain; Dubois, Sydney; Sola, Brigitte; Ochmann, Marlène; Lemonnier, François; Viailly, Pierre-Julien; Bertrand, Philippe; Maingonnat, Catherine; Traverse-Glehen, Alexandra; Gaulard, Philippe; Damotte, Diane; Delarue, Richard; Haioun, Corinne; Argueta, Christian; Landesman, Yosef; Salles, Gilles; Jais, Jean-Philippe; Figeac, Martin; Copie-Bergman, Christiane; Molina, Thierry Jo; Picquenot, Jean Michel; Cornic, Marie; Fest, Thierry; Milpied, Noel; Lemasle, Emilie; Stamatoullas, Aspasia; Moeller, Peter; Dyer, Martin J S; Sundstrom, Christer; Bastard, Christian; Tilly, Hervé; Leroy, Karen.
Afiliação
  • Jardin F; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Pujals A; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Pelletier L; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Bohers E; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Camus V; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Mareschal S; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Dubois S; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Sola B; Departement of Hematology, Normandie Univ, UNICAEN, Caen, EA4652, France.
  • Ochmann M; Departement of Hematology, Inserm U917, CHU Pontchaillou, Rennes, France.
  • Lemonnier F; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Viailly PJ; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Bertrand P; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Maingonnat C; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Traverse-Glehen A; Departement of Hematology, Inserm U917, CHU Pontchaillou, Rennes, France.
  • Gaulard P; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Damotte D; Departement of Hematology, Hospices Civils De Lyon, Lyon-1 University, Pierre Benite, CNRS UMR5239, France.
  • Delarue R; Department of Pathology, Hôpitaux Universitaires, Paris Centre, Team « Cancer, Immune Control, and Escape ¼ INSERM U1138, Cordeliers Research Center, Paris, France.
  • Haioun C; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Argueta C; Department of Hematology, Necker Hospital, AP-HP, Paris, France.
  • Landesman Y; Department of Hematology, Necker Hospital, AP-HP, Paris, France.
  • Salles G; Karyopharm Therapeutics, Newton, MA.
  • Jais JP; Department of Biostatistics, Hopital Necker, Paris, France.
  • Figeac M; Departement of Genomics, Functional Genomic Platforms, IRCL, Lille, France.
  • Copie-Bergman C; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
  • Molina TJ; Department of Pathology, Necker Hospital, AP-HP, Paris, France.
  • Picquenot JM; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Cornic M; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Fest T; Departement of Hematology, Inserm U917, CHU Pontchaillou, Rennes, France.
  • Milpied N; Department of Hematology, CHU De Bordeaux, France.
  • Lemasle E; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Stamatoullas A; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Moeller P; Department of Pathology, Institute of Pathology, University of Ulm, Germany.
  • Dyer MJ; Department of Hematology, Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.
  • Sundstrom C; Department of Pathology, Uppsala, Sweden.
  • Bastard C; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Tilly H; Departement of Hematology, Inserm U918, Centre Henri Becquerel, Rouen, France.
  • Leroy K; Departement of Hematology, Inserm U955 Team 09, APHP Hospital Henri Mondor, Créteil, France.
Am J Hematol ; 91(9): 923-30, 2016 09.
Article em En | MEDLINE | ID: mdl-27312795
Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-ß nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased cell-death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein. Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Receptores Citoplasmáticos e Nucleares / Transporte Ativo do Núcleo Celular / Carioferinas / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Receptores Citoplasmáticos e Nucleares / Transporte Ativo do Núcleo Celular / Carioferinas / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França